Skip to content

The Study of the Phenotype of Hereditary Xerocytosis

The Study of the Phenotype of Hereditary Xerocytosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06892171
Acronym
EPIOX
Enrollment
20
Registered
2025-03-24
Start date
2025-03-01
Completion date
2028-03-31
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genotype, Phenotype, Xerocytosis

Keywords

xerocytosis, phenotype, genotype, PIEZO1, KCNN4 mutation

Brief summary

Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.

Interventions

BIOLOGICALBlood sample

blood sample for genetic analysis

Sponsors

Kremlin-Bicetre Hospital, Paris
CollaboratorUNKNOWN
Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient diagnosed with hereditary xerocytosis according to the 2021 PNDS guidelines * Covered by a social security plan * Signature of the consent form for study participation by the patient, or for minors, by the parent(s)/legal representative(s).

Exclusion criteria

* patients with other hemolysis reason

Design outcomes

Primary

MeasureTime frame
identification of PIEZO1 mutations36 months
identification of KCNN4 mutations36 months
correlation between the identified PIEZO1 mutations and Hemoglobin levels36 months
correlation between the identified KCNN4 mutations and Hemoglobin levels36 months
correlation between the identified PIEZO1 mutations and reticulocytes levels36 months
correlation between the identified KCNN4 mutations and reticulocytes levels36 months
correlation between the identified PIEZO1 mutations and Ferritin levels36 months
correlation between the identified KCNN4 mutations and Ferritin levels36 months
correlation between the identified PIEZO1 mutations and MRI quantification of intrahepatic iron36 months
correlation between the identified KCNN4 mutations and MRI quantification of intrahepatic iron36 months

Countries

France

Contacts

Primary ContactLoic Garçon, Pr
garcon.loic@chu-amiens.fr33+322088371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026